Management of Hypertension in Patients on Beta Blockers and ACE Inhibitors

Introduction to Guideline Recommendations

The American College of Cardiology recommends decreasing or discontinuing the beta blocker first while maintaining the ACE inhibitor in patients requiring blood pressure reduction who are on both medications, due to the superior cardiovascular and renal protective effects of ACE inhibitors 1, 2, 3.

ACE inhibitors are foundational therapy for hypertension management and provide proven benefits in reducing cardiovascular events, particularly in patients with diabetes, chronic kidney disease, or established cardiovascular disease, as recommended by the American Heart Association and the European Society of Cardiology 4, 5.
The American College of Cardiology and the European Society of Cardiology guidelines recommend ACE inhibitors (or ARBs) as first-line agents for most patients with hypertension, particularly those with compelling indications 4, 5, 6.

Beta blockers are less effective for stroke prevention compared to other antihypertensive classes and are now considered primarily indicated for specific cardiac conditions (heart failure, post-MI, angina) rather than uncomplicated hypertension, according to the American College of Cardiology 4.
The European Society of Cardiology guidelines specifically note that beta blockers should be reserved for patients with specific cardiac indications rather than as routine first-line therapy for hypertension 4.

Determine if the patient has heart failure with reduced ejection fraction (HFrEF), post-MI status, or chronic angina—these are compelling indications for beta blocker continuation, as stated by the American College of Cardiology and the European Society of Heart Failure 1, 2.
Evaluate for volume overload that may be contributing to elevated BP; if present, optimize diuretic therapy first before reducing either agent, recommended by the American College of Cardiology and the European Society of Heart Failure 1, 2.
Reduce the beta blocker dose by 50% as the first intervention, and monitor blood pressure and heart rate over 24-48 hours, as suggested by the American College of Cardiology 3.

In patients with HFrEF on guideline-directed medical therapy (GDMT), both ACE inhibitors and beta blockers are Class I recommendations for mortality reduction, according to the American College of Cardiology and the European Society of Heart Failure 1, 2.
If symptomatic hypotension occurs in HFrEF patients, first optimize diuretic therapy to address volume status before reducing either neurohormonal blocker, recommended by the American College of Cardiology and the European Society of Heart Failure 1, 2.

Blood pressure should be monitored frequently (every 15 minutes initially if symptomatic, then daily) after any medication adjustment, as recommended by the American College of Cardiology 8.
Heart rate monitoring is essential after beta blocker reduction to detect rebound tachycardia, suggested by the American College of Cardiology 3.
Assess for symptoms of hypoperfusion (dizziness, lightheadedness, fatigue, oliguria) rather than relying solely on blood pressure numbers, recommended by the American College of Cardiology and the European Society of Heart Failure 1, 2.